Search for European Projects

34 European Projects Found

Searched on 125080 European Projects

 ONGOING 
Fifteen years ago it was widely believed that asthma was an allergic/atopic disease caused by allergen exposure in infancy; this produced atopic sensitization and continued exposure resulted in eosinophilic airways inflammation, bronchial hyper-responsiveness and reversible airflow obstruction. It is now clear that this model is at best incomplete. Less than one-half of asthma cases involve allerg ...
Read Project

 6

 ONGOING 
Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge!Antibiotic resistance is a global public health concern recently elevated to the top three threats identified by the WHO, and subject of numerous national and international government activities. Although focused strategies have beneficially influenced infection rates due to methicillin resistant Staphylococcus aureus (M ...
Read Project

 23

 ONGOING 

European Gram Negative Antibacterial Engine (ENABLE)

Start date: Feb 1, 2014, End date: Jan 31, 2020,

The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens. There is a growing concern that the loss of therapeutic options will present us with a post-antibiotic era where present and future medical advances are negated. Resistant bacteria dramatically reduce the possibilities of treating infections effectively, a ...
Read Project

 42

 FINISHED 
Vancomycin is the critically important antibiotic to treat neonatal Late Onset Sepsis (LOS) due to Gram positive bacteria in neonates, including Coagulase Negative Staphylococci (CoNS) and Staphylococcus aureus. These organisms also create biofilms which are extremely resistant to antibiotics. The increased incidence of LOS due to bacteria such as CoNS and MRSA in NICUs has led to a marked increas ...
Read Project

 14

 FINISHED 

Eliciting Mucosal Immunity to Tuberculosis (EMI-TB)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year. The only currently available vaccine, Mycobacterium bovis BCG, is effective against severe childhood forms, but it demonstrates a variable efficacy against the pulmonary form of TB in adults. Many of these adult TB cases result from the reactivation of an initially controlled, latent Mycobacterium tuberculosis ...
Read Project

 15

 FINISHED 
Smoking is the largest avoidable cause of preventable morbidity worldwide. It causes most of the cases of lung cancer and chronic obstructive pulmonary disease (COPD) and contributes to the development of other lung diseases. The control of smoking is considered as a highly important intervention for the prevention of lung diseases. Tobacco consumption is highly influenced by socioeconomic factors ...
Read Project

 14

 FINISHED 
The PHOCNOSIS project aims at the development and the preclinical validation of a nanotechnology-based handheld point-of-care testing (POCT) analysis device for its application in the early diagnosis of cardiovascular diseases (CVD). The diagnosis will be carried out by means of the fast (
Read Project

 10

 FINISHED 
Biopharmaceutical proteins are typically produced in cultivated mammalian cells, a costly process with limited scalability. Thus products such as monoclonal antibodies are very expensive and often beyond the reach of the world’s poor. The problem is compounded by the fact that important strategies for preventing diseases such as HIV and rabies typically involve large doses of multiple antibodies a ...
Read Project

 2

 FINISHED 
Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical sy ...
Read Project

 23

 FINISHED 

Advanced Immunization Technologies (ADITEC)

Start date: Oct 1, 2011, End date: Sep 30, 2017,

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Read Project

 53

 FINISHED 

Global Research in Paediatrics (GRiP)

Start date: Jan 1, 2011, End date: Jun 30, 2017,

Paediatric drugs (PD) lack appropriate testing. Most drugs have inadequate information about dosing regimen, dose adjustment and how to administer them. These are longstanding problems that unquestionably require concerted efforts at the international level. Both the US and the EU have introduced paediatric legislation that facilitates participation of children in research and pharmaceutical innov ...
Read Project

 24

 FINISHED 

Biomarkers For Enhanced Vaccine Safety (BIOVACSAFE)

Start date: Mar 1, 2012, End date: Dec 31, 2016,

BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveil ...
Read Project

 24

 FINISHED 
... ly damaged and usually die but cellular loss can occur hours and days thereafter. These diseases cause massive morbidity and mortality and tremendous economic and societal burden, especially ischemic stroke, which is a leading cause of death and disability with no effective treatment to promote recovery. The brain responds to a stroke, i.e., occlusion of a cerebral artery, with an inflammatory pro ...
Read Project

 10

 FINISHED 
Outbreaks of clinical infections affect many thousands of patients in Europe yearly. The present effective treatment for infections is large doses of systemically applied drugs. There is a high risk of recurring infections and biofilm formation for patients dependent on long term in-dwelling catheters and the extended dependency on antibiotics result in clinical drug resistance. We present a new t ...
Read Project

 7

 FINISHED 

Cutaneous and Mucosal HIV Vaccination (CUT'HIVAC)

Start date: Jan 1, 2010, End date: Dec 31, 2015,

Despite significant effort over the past decade to design and implement new vaccines strategies against HIV, no one has met its promise to prevent infection and/or to reduce viral load until reaching eradication of the HIV reservoir. To reach this goal, a translational research is critical to propose innovative approaches for an HIV vaccine enhancing broadly cross-reactive mucosal, humoral and cel ...
Read Project

 18

 FINISHED 
For decades, researchers have used small mammals to study the underlying processes of human disease and potential therapies for such ailments. Current strategies for measuring disease progression and/or drug effect usually involve groups of animals being killed at multiple time points for post-mortem tissue analysis. Recently, transgenic strains of mice have been created in which light-emitting lu ...
Read Project

 3

 FINISHED 
"The initiation and perpetuation of atrial fibrillation (AF) can be regarded as a complication of a progressive transformation of the structure and functional properties of the atria. This transformation is the result of complex and multiple changes at the molecular, cellular and organ levels which interact to form the basis for proarrhythmic mechanisms in AF. Numerous individual and environmental ...
Read Project

 20

 FINISHED 

Combined Highly Active Anti-retroviral Microbicides (CHAARM)

Start date: Jan 1, 2010, End date: Jun 30, 2015,

This proposal is for a large scale collaborative project in which we propose both to develop novel microbicides directed against new intracellular targets and to investigate novel combinations of highly active anti-retroviral drugs which may be particularly effective as microbicides. Combinations may enhance efficacy but equally importantly will increase the genetic barrier to the development of r ...
Read Project

 34

 FINISHED 
Previous studies have demonstrated the high frequency of bacterial sepsis in neonates and infants admitted to neonatal intensive care unit (NICU), often associated with serious complications or death. Many pathogens capable of causing nosocomial bacterial sepsis in neonates and young infants have developed resistance to the antibiotics considered of choice for treatment. Meropenem is an antibiotic ...
Read Project

 12

 FINISHED 
... e elimination of malaria in different countries depends critically on provision of effective antimalarials and further that these antimalarials are used appropriately in individual patients. Drug resistance is a major threat to malaria control and has important global public health implications. Over the past decades the genetic bases for resistance to most of the antimalarial classes currently in ...
Read Project

 4

 FINISHED 
... h experiments are referred to as omic data, to indicate their genome-wide coverage. Advances in biotechnology have resulted in the possibility to obtain a growing variety of omic datasets. However, most computational and algorithmic efforts have been directed at mining data from each of these molecular levels (genomic, transcriptomic, etc.) separately and combining the results in order to explore ...
Read Project

 4

 FINISHED 
The main purpose of RESCAP-MED is to enhance the non-communicable diseases (NCDs) research landscape in southern and eastern Mediterranean countries by (a) strengthening capacity in a set of disciplines most relevant to improving public health and reducing health inequalities, and (b) enhancing networking, cooperation, and collaboration between researchers in the Mediterranean region. The main co ...
Read Project

 12

 FINISHED 

EUROpean consortium on NEUTralising antibodies using gp41 (EURONEUT-41)

Start date: Jan 1, 2008, End date: Mar 31, 2014,

There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed ...
Read Project

 19

 FINISHED 
... ion has never been better. However, serious public health problems remain, which cannot be ignored including high levels of premature death due to cardiovascular diseases. Thus, new preventive, diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases are needed. The atherosclerotic changes of the vascular wall are central in the development of cardiovascular complicat ...
Read Project

 19

 FINISHED 

Arrhythmogenic potential of drugs (ARITMO)

Start date: Jan 1, 2010, End date: Jun 30, 2013,

... e in the QT interval does not necessarily lead to TdP which further increased the regulatory and clinical difficulties. This proposal will assess the arrhythmogenic potential of antipsychotics, antihistamines and anti-infectives (> 250 compounds). It will fulfill this aim by: reviewing the literature on in-vitro and in-vivo preclinical evidence; conducting in-silico modeling to predict the arrh ...
Read Project

 21

 FINISHED 
Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, is a neglected bacterial infection of the poor in remote rural areas, mostly affecting children. BUD, the third most common mycobacterial disease in immunocompetent humans after tuberculosis and leprosy, is most endemic in West Africa, but cases have been reported from more than 30 countries. BUD is a mutilating disease leading to sever ...
Read Project

 16

 FINISHED 

Access to Pharmaceuticals (ATP)

Start date: Oct 1, 2009, End date: Mar 31, 2013,

... ls Equitable access to pharmaceuticals, particularly for developing countries is an essential human right. Various complex impediments hinder access, which is the subject of ongoing multidisciplinary studies. Intellectual Property and product development are two issues that can be used as tools to address the problem of access, particularly to make patented drugs more affordable and accessible. Th ...
Read Project

 5

 FINISHED 
The CoMoFarm project will establish high-yielding production systems for pharmaceutical and industrial proteins based on plants, plant tissue and plant cells. The aim is to develop systems in which both the production host and the product itself show consistent yield and quality. The project will include a comparison of four alternative systems – hydroponic plants, root cultures, moss and suspensi ...
Read Project

 10

 FINISHED 

Intervention strategies against malaria (InterMalTraining)

Start date: Oct 1, 2008, End date: Sep 30, 2012,

Malaria exacts a devastating social and economic cost across the globe. Europe is at the forefront of the battle against this disease. It contains many of the leading malaria research groups, most of which are members of at least one of two consortia; BioMalPar, a Network of Excellence focused on basic research into the biology and pathology of malaria; and AntiMal, an integrated project aiming ...
Read Project

 13

 FINISHED 

Multicentre discovery of breast cancer biomarkers (CANOMICS)

Start date: Aug 1, 2010, End date: Jul 31, 2012,

"Breast cancer is the most common cause of death from cancer among European women, and over half of the worldwide breast cancer related mortalities occur in the developing world. Despite improvements in surgical techniques and chemoradiotherapy, the ability to cure patients with breast cancer remains limited and five year survival for patients with advanced disease is dismal. Expression profiling ...
Read Project

 4

 FINISHED 

Signalling in life cycle stages of malaria parasites (MALSIG)

Start date: Feb 1, 2009, End date: Jul 31, 2012,

Malaria is a major public health problem in the developing world and is endemic in many regions of India. The development of novel strategies for malaria control requires a better understanding of the biology of malaria parasites. Our project aims at bringing a significant contribution to this field, through dissecting the signalling pathways that regulate essential processes in the life cycle o ...
Read Project

 18

 FINISHED 

Fighting Aneurysmal Diseases (FAD)

Start date: Jul 1, 2008, End date: Jun 30, 2012,

... ation. In the absence of intervention, aneurysms evolve towards rupture and death. The translational objectives of the project are to accelerate the acquisition of knowledge, and to develop new diagnostic and therapeutic tools for FAD in humans. The project innovates by integrating two different localizations differing in their initial etiologies but similar in their evolution. FAD will be built b ...
Read Project

 15

 FINISHED 
"Methicillin-resistant Staphylococcus aureus (MRSA) are of increasing concern both as community- and hospital-acquired pathogens. Since 2005, a specific clone, MRSA ST398 is spreading both in livestock populations and occupationally-exposed people resulting in human infection and disease in several EU Member States. The key objective of the PILGRIM project is to provide a range of novel control m ...
Read Project

 12

 FINISHED 
Although the definition of latency under a clinical point of view seems clear, the bacterial biology behind that clinical situation remains poorly understood. While dormant, the tubercle bacilli are considered to be under non-replicating (NR) stage. In such a condition, bacilli are not only difficult to be detected but also refractory to the standard treatments avoiding their clearance from the in ...
Read Project

 7